Atea Pharmaceuticals is expected to report a Q2 2026 consensus loss of $0.56 per share on $0.00 in revenue, with its current stock price of approximately $4.61 trading significantly below the average analyst price target of $8.67. The primary focus for investors during this earnings call will be the clinical development progress and regulatory path for the bemnifosbuvir and ruzasvir combination therapy for Hepatitis C.
This report follows the company's late July announcement that its Phase 3 C-BEYOND North America trial successfully met all primary and secondary endpoints. Analysts are now looking for updates on the global C-FORWARD trial and confirmation of the company's cash runway, which was previously projected to extend through 2027.